Microsatellite instability in colorectal cancer
Microsatellite instability (MSI) is a hypermutable phenotype caused by the loss of DNA
mismatch repair activity. MSI is detected in about 15% of all colorectal cancers; 3% are of …
mismatch repair activity. MSI is detected in about 15% of all colorectal cancers; 3% are of …
The evolving role of microsatellite instability in colorectal cancer: a review
F Gelsomino, M Barbolini, A Spallanzani… - Cancer treatment …, 2016 - Elsevier
Microsatellite instability (MSI) is a molecular marker of a deficient mismatch repair (MMR)
system and occurs in approximately 15% of colorectal cancers (CRCs), more frequently in …
system and occurs in approximately 15% of colorectal cancers (CRCs), more frequently in …
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
S Venderbosch, ID Nagtegaal, TS Maughan… - Clinical Cancer …, 2014 - AACR
Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR)
status and its relation to BRAF mutation (BRAF MT) status in metastatic colorectal cancer …
status and its relation to BRAF mutation (BRAF MT) status in metastatic colorectal cancer …
Colorectal cancer liver metastases–a population-based study on incidence, management and survival
J Engstrand, H Nilsson, C Strömberg, E Jonas… - BMC cancer, 2018 - Springer
Background Colorectal cancer (CRC) is a leading cause of cancer-associated deaths with
liver metastases developing in 25–30% of those affected. Previous data suggest a survival …
liver metastases developing in 25–30% of those affected. Previous data suggest a survival …
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
F Di Nicolantonio, M Martini, F Molinari… - Journal of clinical …, 2008 - ascopubs.org
Purpose Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic
colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40 …
colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40 …
Mortality by stage for right-versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results–Medicare data
JM Weiss, PR Pfau, ES O'Connor, J King… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Recent studies have reported increased mortality for right-sided colon cancers but
had limited adjustment for patient characteristics and conflicting results by stage. We …
had limited adjustment for patient characteristics and conflicting results by stage. We …
Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers
Purpose: Tumor-infiltrating T lymphocytes (TIL) play a key role in the clinical outcome of
human colorectal cancer; however, the dynamics of their recruitment along colorectal cancer …
human colorectal cancer; however, the dynamics of their recruitment along colorectal cancer …
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M Koopman, GAM Kortman, L Mekenkamp… - British journal of …, 2009 - nature.com
A deficient mismatch repair system (dMMR) is present in 10–20% of patients with sporadic
colorectal cancer (CRC) and is associated with a favourable prognosis in early stage …
colorectal cancer (CRC) and is associated with a favourable prognosis in early stage …
S3-leitlinie–kolorektales karzinom
W Schmiegel, B Buchberger… - Zeitschrift für …, 2017 - thieme-connect.com
2.1 Geltungsbereich und Zweck 2.1. 1. Zielsetzung und Fragestellung Das Kolorektale
Karzinom (KRK) ist mit etwa 64 000 Neuerkrankungen und ca. 26 000 Todesfällen pro Jahr …
Karzinom (KRK) ist mit etwa 64 000 Neuerkrankungen und ca. 26 000 Todesfällen pro Jahr …
Is there a difference in survival between right-versus left-sided colon cancers?
Background The incidence of right-sided colon cancers has been increasing in recent years.
It is unclear whether patient prognosis varies by tumor location. In this study, we have …
It is unclear whether patient prognosis varies by tumor location. In this study, we have …